{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:34:09Z","timestamp":1778582049243,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007920","name":"University of Massachusetts Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.molmed.2021.02.004","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T01:36:01Z","timestamp":1615426561000},"page":"520-523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["AAV-Mediated Gene Therapy for Glycosphingolipid Biosynthesis Deficiencies"],"prefix":"10.1016","volume":"27","author":[{"given":"Huiya","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Robert H.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin A.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2021.02.004_bb0005","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibs.2015.03.007","article-title":"Gangliosides: glycosphingolipids essential for normal neural development and function","volume":"40","author":"Schengrund","year":"2015","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.molmed.2021.02.004_bb0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/mus.24336","article-title":"Natural history and biomarkers in hereditary sensory neuropathy type 1","volume":"51","author":"Fridman","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.molmed.2021.02.004_bb0015","doi-asserted-by":"crossref","first-page":"14646","DOI":"10.1523\/JNEUROSCI.2536-09.2009","article-title":"Overexpression of the wild-type SPT1 subunit lowers desoxysphingolipid levels and rescues the phenotype of HSAN1","volume":"29","author":"Eichler","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.molmed.2021.02.004_bb0020","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/ng1460","article-title":"Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase","volume":"36","author":"Simpson","year":"2004","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2021.02.004_bb0025","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ymgme.2019.01.013","article-title":"Recessive GM3 synthase deficiency: Natural history, biochemistry, and therapeutic frontier","volume":"126","author":"Bowser","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.molmed.2021.02.004_bb0030","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1073\/pnas.0635898100","article-title":"Enhanced insulin sensitivity in mice lacking ganglioside GM3","volume":"100","author":"Yamashita","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2021.02.004_bb0035","doi-asserted-by":"crossref","first-page":"9483","DOI":"10.1073\/pnas.0903279106","article-title":"Mice lacking ganglioside GM3 synthase exhibit complete hearing loss due to selective degeneration of the organ of Corti","volume":"106","author":"Yoshikawa","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2021.02.004_bb0040","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1126\/science.803227","article-title":"Deficient ganglioside biosynthesis: a novel human sphingolipidosis","volume":"187","author":"Fishman","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.molmed.2021.02.004_bb0045","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ajhg.2013.05.006","article-title":"Alteration of ganglioside biosynthesis responsible for complex hereditary spastic paraplegia","volume":"93","author":"Boukhris","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.molmed.2021.02.004_bb0050","doi-asserted-by":"crossref","first-page":"7532","DOI":"10.1073\/pnas.96.13.7532","article-title":"Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects","volume":"96","author":"Sheikh","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2021.02.004_bb0055","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2021.02.004_bb0060","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","article-title":"Therapeutic AAV gene transfer to the nervous system: a clinical reality","volume":"101","author":"Hudry","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.molmed.2021.02.004_bb0065","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/mt.2010.279","article-title":"MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression","volume":"19","author":"Xie","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2021.02.004_bb0070","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ymthe.2019.11.018","article-title":"Effective and accurate gene silencing by a recombinant AAV-compatible microRNA scaffold","volume":"28","author":"Xie","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2021.02.004_bb0075","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1016\/j.febslet.2015.09.018","article-title":"Ganglioside GM3 as a gatekeeper of obesity-associated insulin resistance: evidence and mechanisms","volume":"589","author":"Lipina","year":"2015","journal-title":"FEBS Lett."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491421000484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491421000484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:21:23Z","timestamp":1761463283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491421000484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1471491421000484"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2021.02.004","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV-Mediated Gene Therapy for Glycosphingolipid Biosynthesis Deficiencies","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2021.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}